Written in Blood

Written in Blood

Research from recent issues of Blood

WIB_icon

Brentuximab Vedotin Active in Relapsed/Refractory B-Cell Lymphoma

For patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are ineligible for transplant or fail to respond to salvage regimens, treatment with brentuximab...
WIB_icon

Superficial Vein Thromboses Put People at Risk for Subsequent Blood Clots

Until recently, a superficial vein thrombosis (SVT) was seen as a painful induration of limited clinical significance. New evidence from a large population-based study...
WIB_icon

Brentuximab Vedotin: Changing the Landscape for Relapsed/Refractory Hodgkin Lymphoma Patients?

For the approximately 50 percent of patients with relapsed/refractory Hodgkin lymphoma who do not respond to autologous stem cell  transplantation (auto-SCT), the antibody-drug conjugate brentuximab vedotin produced durable response and survival, according to...
WIB_icon

Phase 2 Results of the Carfilzomib, Thalidomide, and Dexamethasone (KTd) Regimen in Multiple Myeloma...

Appropriate selection of induction and consolidation chemotherapy regimens is essential to achieving the maximum response and improving outcomes for patients with multiple myeloma (MM) planning to undergo...
WIB_icon

Biologics Before Chemotherapy: Treatment Updates for Mycosis Fungoides, Sézary Syndrome

The use of chemotherapy to treat mycosis fungoides and Sézary syndrome, the most common forms of cutaneous T-cell lymphomas, led to a shorter time...
WIB_icon

Off-Label Rituximab Proves Its Mettle in Adult ITP

For adult patients with persistent or chronic immune thrombocytopenia (ITP), off-label treatment with rituximab proved a safe and effective management option, according to results...
WIB_icon

Pre-Procedure Anticoagulation Interruption May Not Be Necessary

Patients with atrial fibrillation (AF) on anticoagulation therapies who require a surgical procedure may require an interruption in the therapy – depending on their...
WIB_icon

Obesity Has Early and Lasting Effects on Children with ALL

For children with B-precursor acute lymphocytic leukemia (BP-ALL), having a BMI ≥30 kg/m2 at the time of treatment initiation more than doubled the likelihood...
WIB_icon

Remission Duration Key to Survival in CLL After FCR

In spite of the efficacy of the treatment regimen of fludarabine, cyclophosphamide, and rituximab (FCR) in chronic lymphocytic leukemia (CLL), most CLL patients are...
WIB_icon

Once-Weekly Bortezomib Produced Durable Responses, Survival in Relapsed AL Amyloidosis

Results from a phase I/II study of single-agent bortezomib suggest that a once-weekly dosing regimen produced similar efficacy results to a twice-weekly regimen —...
Advertisement

Current Issue

March 2019, Volume 5, Issue 4

This issue features a look at the misconceptions about travel-associated blood clots, the treatment of young patients with myeloma, and more.